Span Divergent Ltd (524727)
Latest quarterly results (Q1 FY27)
In its latest reported quarter, Q1 FY27, Span Divergent's revenue was ₹1.0 Cr (-4.8% year on year, -78.1% on the previous quarter), and net profit ₹-1.2 Cr (a bigger loss than a year earlier); the operating margin was -102.9%.
| Q1 FY27 (₹ Cr) | Value | YoY vs Q1 FY26 | QoQ |
|---|---|---|---|
| Revenue | ₹1.0 | -4.8% | -78.1% |
| Operating profit | ₹-1.0 | loss widened | loss widened |
| Net profit | ₹-1.2 | loss widened | loss widened |
| EPS (₹) | -1.64 | loss widened | loss widened |
| Operating margin | -102.9% | — | — |
📢 Recent Corporate Announcements
Span Divergent reported a weak Q1 FY27 (ending June 2026) with consolidated total income falling 27.3% YoY to ₹1.30 Cr from ₹1.79 Cr. The company posted a consolidated net loss of ₹10.96 Lakhs, a sharp reversal from the ₹14.50 Lakhs profit recorded in the same quarter last year. Standalone operations were particularly weak, with total income halving to ₹30.83 Lakhs. The company continues to struggle with loss-making subsidiaries, one of which has a negative net worth of ₹7.52 Cr.
- Consolidated total income declined to ₹130.20 Lakhs from ₹179.21 Lakhs in the year-ago quarter.
- Consolidated net loss stood at ₹10.96 Lakhs compared to a profit of ₹14.50 Lakhs in Q1 FY26.
- Subsidiary Aranya Consulting and Biotech LLP reported accumulated losses of ₹14.94 Cr as of March 31, 2026.
- Biospan Contamination Control Solutions Pvt Ltd has a negative net worth, with liabilities exceeding assets by ₹7.52 Cr.
- Unutilized proceeds from the October 2025 preferential issue stand at ₹217.06 Lakhs out of ₹579.30 Lakhs raised.
Span Divergent reported a weak Q1 FY27 with consolidated total income falling to ₹1.30 Cr from ₹1.79 Cr in the year-ago period. The consolidated loss before tax widened significantly to ₹1.15 Cr, compared to a loss of ₹0.33 Cr in Q1 FY26. The company's financial health is under pressure from its subsidiaries, particularly Biospan Contamination Control, which has a negative net worth of ₹7.52 Cr. Furthermore, ₹2.11 Cr remains unutilized from the ₹5.79 Cr preferential issue raised in October 2025, intended for inventory and operational ramp-up.
- Consolidated total income decreased by 27% YoY to ₹1.30 Cr in Q1 FY27.
- Consolidated loss before tax widened to ₹1.15 Cr from ₹0.33 Cr in the previous year's corresponding quarter.
- Subsidiary Biospan Contamination Control Solutions Pvt Ltd reports a negative net worth of ₹7.52 Cr with liabilities exceeding assets.
- Aranya Consulting and Biotech LLP subsidiary has accumulated losses totaling ₹14.94 Cr as of March 31, 2026.
- ₹2.11 Cr of the ₹5.79 Cr raised via preferential issue on October 15, 2025, remains unutilized.
Span Divergent Ltd has scheduled a board meeting for August 11, 2026, to approve its unaudited standalone and consolidated financial results for the quarter ended June 30, 2026. The company is currently in a challenging financial position, reporting a TTM loss of ₹3 Cr on revenue of ₹17 Cr. Investors should note the significant drop in promoter holding from 64% in December 2025 to 48.13% in March 2026. The upcoming results will be critical to assess if the company can improve its operating profit margin, which stood at -15.1% for the trailing twelve months.
- Board meeting scheduled for August 11, 2026, to consider Q1 FY27 results
- Company reported a TTM revenue of ₹17 Cr against a market cap of ₹23 Cr
- Net loss for FY26 widened to ₹2.95 Cr compared to a loss of ₹1.28 Cr in FY25
- Promoter holding saw a sharp decline to 48.13% as of the March 2026 quarter
- Trading window for insiders is closed until 48 hours after the result declaration
Financial Performance
Financial analysis data not yet available for this company.
Operational Drivers
Operational analysis data not yet available for this company.
Strategic Growth
Strategic growth analysis not yet available for this company.
External Factors
External factors analysis not yet available for this company.
Regulatory & Governance
Regulatory analysis not yet available for this company.
Risk Analysis
Risk analysis not yet available for this company.
